Epaminurad

DB18973InvestigationalSmall molecule

Epaminurad is under investigation in clinical trial NCT05815901 (A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients).

Mechanism: Pharmacologically active on Solute carrier family 22 member 12
Curator reviewed
Formula / weight: C₁₄H₁₀Br₂N₂O₃ · 414.053 g/mol (avg)
Also known as: (3,5-dibromo-4-hydroxyphenyl)(2,3-dihydro-4h-pyrido(4,3-b)-1,4-oxazin-4-yl)methanone · Methanone, (3,5-dibromo-4-hydroxyphenyl)(2,3-dihydro-4h-pyrido(4,3-b)-1,4-oxazin-4-yl)-
Code names: UR-1102

Resolves to

Compound

UNII0YP1ME85GHCAS1198153-15-9ChEMBLCHEMBL4640580

Structure

InChIKeyZMVGQIIOXCGAFV-UHFFFAOYSA-NSMILESOC1=C(Br)C=C(C=C1Br)C(=O)N1CCOC2=CC=NC=C12

Targets

Q96S37SLC22A12

Transporters

Q4U2R8SLC22A6Q8TCC7SLC22A8

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2TransportersSubstrate / inhibitor direction, not just membership

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Epaminurad, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In